Literature DB >> 11792594

Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies.

J A Kanis1, O Johnell, A Oden, C De Laet, B Jonsson, A Dawson.   

Abstract

Bone mineral density (BMD) measurements are widely used to estimate the risk of osteoporotic fractures. In addition, many other risk factors have been identified, some of which are known to add to the risk independently of BMD measurements. The combination of BMD with such risk factors increases the gradient of risk/standard deviation (SD) than that achieved by BMD alone. In this paper, we report the fracture probabilities according to age, gender, and relative risk, and have investigated the effects of changes in the gradient of risk for osteoporotic fractures on the sensitivity and specificity of assessments, modeled on the population of Sweden. Ten-year risks of hip, clinical vertebral, forearm, or proximal humeral fracture were computed with increments in gradient of risk that varied from 1.5 to 6.0 per SD change in skeletal risk. The identification of high-risk groups had little effect on the specificity of assessments, but increased the sensitivity over a wide range of assumptions. The inclusion of all four fracture types had little effect on sensitivity, but increased the positive predictive value of the test. Positive predictive value also increased with age, so that values greater than 50% were obtained testing women at the age of 65 years with modest gradient of risk of 2.0-2.5/SD when small segments of the population were targeted (0.5-5%). Screening of women to direct intervention at the age of 65 years and targeting 25% of the population could save up to 23% of all fractures in women over the next 10 years by the use of multiple tests with a moderate gradient of risk (RR = 2.0/SD). Such gradients might be achieved with the use of multiple risk factors to identify patients at risk.

Entities:  

Mesh:

Year:  2002        PMID: 11792594     DOI: 10.1016/s8756-3282(01)00653-6

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  64 in total

Review 1.  Preventing fractures in elderly people.

Authors:  Anthony D Woolf; Kristina Akesson
Journal:  BMJ       Date:  2003-07-12

2.  Action Plan for the prevention of osteoporotic fractures in the European Community.

Authors:  Juliet Compston
Journal:  Osteoporos Int       Date:  2004-02-18       Impact factor: 4.507

3.  An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines.

Authors:  R Baddoura; H Awada; J Okais; M Salamoun; G Ayoub; N Ziadé; G El Hajj-Fuleihan
Journal:  Osteoporos Int       Date:  2006-05-03       Impact factor: 4.507

Review 4.  The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry.

Authors:  John A Kanis; Ego Seeman; Olof Johnell; Rene Rizzoli; Pierre Delmas
Journal:  Osteoporos Int       Date:  2005-02-24       Impact factor: 4.507

Review 5.  Guidelines for the management of osteoporosis: the present and the future.

Authors:  Juliet Compston
Journal:  Osteoporos Int       Date:  2005-06-28       Impact factor: 4.507

Review 6.  The need for microsimulation to evaluate osteoporosis interventions.

Authors:  David J Vanness; Anna N A Tosteson; Sherine E Gabriel; L Joseph Melton
Journal:  Osteoporos Int       Date:  2005-01-11       Impact factor: 4.507

7.  The global perspective of osteoporosis : the ILAR lecture, June 2004, Berlin.

Authors:  Anthony D Woolf
Journal:  Clin Rheumatol       Date:  2006-04-25       Impact factor: 2.980

8.  Absolute fracture risk.

Authors:  Chad L Deal
Journal:  Curr Rheumatol Rep       Date:  2007-04       Impact factor: 4.592

9.  The risk and burden of vertebral fractures in Sweden.

Authors:  J A Kanis; O Johnell; A Oden; F Borgstrom; N Zethraeus; C De Laet; B Jonsson
Journal:  Osteoporos Int       Date:  2003-10-31       Impact factor: 4.507

Review 10.  Bone health and prostate cancer.

Authors:  P J Saylor; M R Smith
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-11-10       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.